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Abstract: Hepatitis C virus (HCV) is the most common blood-borne infection in developed countries and co-infection 
with the Human Immunodeficiency Virus (HIV) is frequent in individuals with history of injecting drug use (IDU). 
We aimed to analyze liver transaminases in HCV monoinfected and HCV/HIV co-infected patients to assess the effect of 
HIV infection on liver enzyme elevations. 
We studied 429 current IDUs admitted to substance abuse treatment (82.5% males). Serum samples for liver tests, HIV in-
fection and viral hepatitis serologies were obtained at admission. Results: Median age was 30 years (IQR:27-34), median 
duration of IDU was 10 years (IQR:5-14), 52% of patients were HCV/HIV co-infected, 40.8% were HCV monoinfected, 
and 7.2% were HCV and HIV- seronegatives. Elevated AST was associated with male gender and lower CD8
+ cell count 
in the HCV monoinfected patients, and with age and lower cholesterol in the HCV/HIV coinfected subjects. ALT eleva-
tion was associated with younger age, higher body mass index and male gender in the monoinfected patients, and with 
higher CD4
+ cell counts and lower cholesterol in the co-infected group. Male sex was strongly associated with elevated 
ALT and AST transaminase in the monoinfected but not in dual-infected subjects. 
These data suggest that the effect of gender on liver enzymes may be lost in patients with HIV infection. The overall dif-
ferences observed between groups regarding liver enzyme elevations are of clinical relevance in the management of IDUs 
with chronic hepatitis C. 
Keywords: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), correlates of hepatic transaminase elevations, 
HIV/hepatitis C co-infection, injection drug users. 
INTRODUCTION 
  Serum transaminase measurements are widely used in the 
management of chronic hepatitis C. Despite intravenous drug 
use has been associated with lower levels of alanine 
aminotransferase (ALT) [1], elevations of liver enzymes are 
frequent in patients with a history of substance abuse. Potential 
cofactors contributing to liver disease in IDUs are viral hepati-
tis, alcohol consumption and drug induced hepatotoxicity. Pre-
vious studies have shown that the HCV-monoinfected indi-
viduals have higher levels of aspartate aminotransferase (AST), 
ALT, and Gamma-Glutamyl-Transferase (GGT) than the unin-
fected [1, 2] and that ALT levels decrease with age [1, 3] and 
have been associated with body mass index (BMI) [4]. 
  HCV is the most common blood-borne infection in devel-
oped countries and injection drug use accounts for 60% of 
new HCV infections [5]. In IDU populations at risk of Human 
Immunodeficiency Virus (HIV) infection, the prevalence of   
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HCV is high due to shared transmission mechanisms; in this 
context of parenteral transmission, hepatitis C virus infection 
is usually acquired at the beginning of injection drug use [6]. 
  The role of liver enzymes in the assessment of chronic 
hepatitis C remains important due to the fact that the major-
ity of clinical indexes estimating the degree of liver fibrosis 
are based in liver transaminases [7-12]; these non-invasive 
methods to estimate liver fibrosis provide information into 
progression of liver disease and they are an important alter-
native to liver biopsy in populations such as IDUs not being 
elegible for liver biopsy 
  Regarding the role of cellular immune response to HCV 
infection it has been thought to be crucial in the inhibition of 
hepatitis C viral replication. Several studies have reported 
that CD8
+ lymphocytes play a key role as effectors of liver 
damage during chronic HCV infection
 [13-15]. On the other 
hand, total serum cholesterol, triglycerides and glucose have 
been linked to liver transaminase levels in healthy popula-
tions [16]. Alterations of lipid metabolism, particularly in 
apolipoproteins B and C have been described in hepatitis C 
with genotype 1b or 3a [17, 18] and hypocholesterolemia has Liver Enzymes in HCV Infected Drug Users  The Open AIDS Journal, 2008, Volume 2    83 
been associated with HCV infection and HCV/HIV coinfec-
tion [19, 20]. 
  The objective of this study is to analyze correlates of 
liver enzyme alterations in HCV monoinfected and 
HCV/HIV co-infected patients with history of IDU to better 
understand the role of HIV infection on liver transaminase 
alterations. 
PATIENTS AND METHODS 
Study Population 
  Between 1994 and 2004, 498 IDUs were admitted to sub-
stance abuse treatment at University Hospital Germans Trias 
i Pujol in Badalona (Spain). Briefly, patients seeking sub-
stance abuse treatment in primary care centers of metropoli-
tan Barcelona (Badalona and Santa Coloma de Gramenet) 
were referred to a four-bed detoxification unit in a tertiary 
hospital. Patients were primarily referred to hospital due to 
severity of addiction. Additional details on the criteria for 
admission and characteristics of patients have been pub-
lished elsewhere [21]. 
  During admission, patients provide data on socio-
demographics (age and gender) and drug use characteristics 
(main drug, duration of injection, alcohol consumption), cur-
rent medications and history of HIV and HCV treatments. 
Patients also provide blood samples for the analysis of liver 
enzymes, total cholesterol, CD4
+ and CD8
+ cells, hepatitis B 
virus surface antigen (HBsAg), HIV, and HCV infections. 
  Liver enzyme testing was performed the same day of 
blood collection using a multi-channel chemistry analyzer 
(DAX-48, Bayer Diagnostics). All analyses were performed 
with reagents and instrumental conditions exactly as speci-
fied by the instrument manufacturer. A normal liver enzyme 
value was defined according to the range established by the 
department of Clinical Chemistry. The range of liver enzyme 
values was characterized as a function of the upper limit of 
normal. Abnormal levels of AST and ALT were defined as > 
35 U/l and > 45 U/l, respectively. An abnormal level of GGT 
was defined as > 85 U/l in males and > 50 U/l in females. 
  HIV infection was determined by enzyme-linked immu-
nosorbent assay. Repeatedly reactive samples were con-
firmed by Western blot. 
  HCV infection was assessed by second- or later genera-
tion enzyme immunoassay (Ortho Diagnostics, Raritan, NJ). 
HCV RNA testing was performed in frozen sera using the 
qualitative COBAS AMPLICOR assay (Roche Diagnostic 
Systems, Branchburg, NJ). This test was applied retrospec-
tively to sera collected during the study period. 
  For the purposes of this study, patients were eligible if 
they had both an HCV and an HIV test during admission. 
Sixty nine cases (13.9%) were excluded from the study 
population: 4 patients because they had liver enzyme eleva-
tions >10-fold above the upper limit of normal (ULN) and 27 
individuals due to missing information on either HCV or 
HIV infection. Among the remaining 467 patients, 38 (8.1%) 
were excluded from the study because of an HCV RNA-
negative test result. 
Statistical Analysis 
  Three groups were defined according to their HCV and 
HIV serostatus: HCV monoinfected, HCV/HIV coinfected and 
those without either infection. The univariate comparison of 
these three groups was carried out by means of either Fisher’s 
exact test for categorical variables or the nonparametric 
Kruskal-Wallis test for quantitative variables. All other analy-
ses were carried out separately for both mono- and coinfected 
patients. Univariate odds ratios of the risk of AST and ALT 
elevations were calculated for men and women. Correlations 
of CD4
+ and CD8
+ cells with liver enzymes were determined 
by means of Pearson’s correlation coefficient. To identify pre-
dictors of elevated values of AST, ALT, and GGT, multivari-
ate logistic regression models were adjusted for age, gender, 
alcohol consumption, duration of injection drug use, BMI, 
total cholesterol, antiretroviral treatment (in case of coinfected 
individuals), CD4
+ cell count, and CD8
+ cell count as possible 
predictors. Stepwise forward selection was used to identify 
predictors among these variables using =0.05 and =0.1 as 
inclusion and exclusion criteria, respectively. The test of 
Hosmer and Lemeshow
 [22] was used to check the goodness-
of-fit of the models. 
  Because of the right-skewed distributions of CD4
+ and 
CD8
+ cell counts and the liver enzymes, the logarithms (base 
10) of the respective values were used for the statistical 
analyses. Due to the fact that the range of the logarithm of 
the number of CD4
+ and CD8
+ cells was close to one, the 
results from the multivariate logistic regression are ex-
pressed as odds ratios corresponding to an increase of a quar-
ter of a logarithm of either CD4
+ or CD8
+ cells. Such an in-
crease is equivalent to an increase from 250 to 450 cells, 
from 400 to 710 cells, or from 600 to 1050 cells. 
  The test results were considered statistically significant 
whenever P<0.05. Statistical analyses were performed with 
SPSS 12.0 (SPSS, Chicago, IL, USA). 
RESULTS 
  A total of 429 IDUs were included in the study, 175 
(40.8%) of whom were HCV
+/ HIV
– (monoinfected pa-
tients). In addition, 223 patients (52%) were HCV
+/HIV
+ co-
infected and, 31 (7.2%) were HCV and HIV seronegative. 
The characteristics of the three groups are shown in Table 1. 
  We observed significant differences in age, alcohol in-
take, and duration of IDU among the groups. On average, 
HCV/HIV coinfected patients were significantly older than 
the non-infected and presented the longest duration of inject-
ing drugs. The median duration of IDU was 12 years in the 
co-infected patients compared to 7.5 years among the mon-
oinfected and 1.5 years among the non-infected patients. The 
highest prevalence of alcohol consumption was observed 
among non-infected patients were almost 50% of them re-
ported alcohol consumption at entry. 
  The median values of total cholesterol and BMI were 
lower among co-infected patients. However, the differences 
in BMI were rather small: 21.5 kg/m
2 among coinfected pa-
tients  vs 21.7 kg/m
2 among non-infected and 22 kg/m
2 
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  Regarding liver enzymes, AST and ALT levels were sig-
nificantly different between the three groups with highest 
median values among the co-infected (AST and GGT) and 
monoinfected patients (ALT), respectively. The median lev-
els of total bilirubin and alkaline phosphatase were similar 
among groups (P>0.1). Finally, whereas the number of CD8
+ 
cells was about the same in all groups, the number of CD4
+ 
cells in the HCV/HIV coinfected patients was, as expected, 
less than a third the level in either of the two other groups. 
  Among the HIV
+ IDUs, only 58 (26.0%) were taking 
antiretroviral treatment at admission. Among those HIV+ 
IDUs not taking ARV medication, 57.7% of them had more 
than 350 CD4
+ cells. 
Prevalence of Elevated AST, ALT, and GGT 
  The proportions of patients with elevated AST, ALT, and 
GGT levels are shown in Table 1. In all cases, the lowest 
proportions of altered levels were observed among the   
non-infected IDUs: 13.3% (AST and ALT) and 10.3% 
(GGT). In order to examine the effect of HIV on the liver 
enzyme alterations of individuals with chronic hepatitis C, 
the non-infected group was excluded from further compari-
sons. 
  Co-infected patients had higher proportions of elevated 
values of AST (54.4% vs 46%) and GGT (34.3% vs 16.8%), 
whereas the proportion of elevated ALT was higher among 
the monoinfected patients (57.5% vs 48.6%). Fisher’s exact 
test showed that differences were significant for ALT 
(P=0.05) and GGT (P<0.001) and of borderline significance 
for AST (P=0.06). 
Effect of Gender 
 Fig.  (1) shows that the proportions of elevated AST and 
ALT levels differed strongly between men and women in the 
monoinfected but not in the co-infected patients. The esti-
mated univariate odds ratios for elevated AST and ALT lev-
els comparing monoinfected men and monoinfected women 
were 5.14 (95% CI:1.86-14.22) and 5.62 (95% CI: 2.25-
14.04), respectively. Contrary to that finding, among co-
infected patients, the corresponding odds ratios did not differ 
significantly (P=0.18 and P=0.39, respectively). 
Effect of Antiretroviral Treatment 
  Among the 58 patients taking antiretroviral treatment, the 
proportion of elevated values was lower in the case of AST 
(48.1% vs 56.5%) and higher in the case of ALT (50% vs 
Table 1.  Baseline Characteristics of 429 IDUs According to HCV and HIV Serostatus 
 
  HCV
+/ HIV
- HCV
+/ HIV
+ HCV
-/ HIV
-  P-Value 
N (%)  175 (40.8)  223 (52.0)  31 (7.2)   
Sociodemographic and drug use 
Male gender  146 (83.4)  179 (80.3)  29 (93.5)  0.167 
Age in years  30 (26-34)  31 (28-35)  27 (23-32)  0.002 
Alcohol consumption > 40 g/day  38 (21.7)  67 (30.0)  15 (48.4)  0.005 
Duration of IDU in years  7.3 (3.9-12.0)  12.0 (8.0-16.0)  1.5 (0.5-6.0)  <0.001 
Liver enzymes and other variables 
Aspartate aminotransferase (U/l)  32.5 (20-56.3)  38 (27-67)  17 (12.8-28.8)  <0.001 
% AST > 35 U/l  46 54.4  13.3   
Alanine aminotransferase (U/l)  54 (22.8-99)  44.5 (27.8-73)  20.5 (12.8-37.3)  <0.001 
% ALT > 45 U/l  57.5 48.6  13.3   
Gamma glutamyltransferase (U/l)  32 (18-52.5)  51 (25-101)  20 (13.5-33)  <0.001 
% GGT >85 (males)/ >50 (females)  16.8 34.3  10.3   
Alkaline phosphatase (U/l)   68.5 (54-81.3)  70 (58.5-88.3)  65.5 (57-88.5)  0.193 
Bilirrubin (mg/100ml)   0.4 (0.3-0.5)  0.4 (0.3-0.6)  0.4 (0.3-0.5)  0.109 
Total cholesterol (mg/100ml)   159 (143-178)  147 (128-166)  174.5 (159-201)  <0.001 
Body mass index (kg/m
2)  22 (20.7-24.2)  21.5 (19.3-23.4)  21.7 (20.4-24.1)  0.037 
HBsAg
+  7 (4.1)  18 (9.0)  1 (3.4)  0.122 
Current use of antiretroviral treatment  --- 58  (26.0)  ---   
Immunological markers 
CD4
+ (cel/l)   1220 (911.3-1429.5)  390 (195.5-650)  1267 (1043-1440)  <0.001 
CD8
+ (cel/l)   864 (701-1134.5)  900 (665.3-1302.8)  891 (725-1120)  0.554 
NOTE. Results are expressed as median (interquartile range) for continuous variables and absolute frequency (% among non-missing observations) for categorical variables. P-values 
by Kruskal-Wallis test (continuous variables) and 
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48.1%) and GGT (37.7% vs 33.1%); however, none of these 
differences were significant (P-values: 0.34, 0.87, and 0.61, 
respectively). 
Correlation of CD4
+ and CD8
+ Cells with Liver Enzymes 
  The four panels in Fig. (2) illustrate the correlation of 
absolute CD4
+ and CD8
+ cell counts with AST and ALT 
levels, including linear regression lines for both the monoin-
fected and co-infected subjects. 
  With respect to CD4
+, a statistically significant association 
was found with ALT levels in the co-infected patients, indicat-
ing that higher values of CD4
+ cells are associated with higher 
values of ALT (P=0.01). For the CD8
+ cells, significant asso-
ciations were observed between AST levels in the monoin-
fected and ALT levels in both mono- and co-infected patients. 
Co-infected patients showed, on average, higher levels of ALT 
with increasing CD8
+ cells, whereas the correlation was nega-
tive in monoinfected individuals. In other words, the higher 
the number of CD8
+ cells, the lower the levels of AST and 
ALT, respectively. However, none of the correlation coeffi-
cients –even though statistically significant- exceeds 0.25. 
Correlation coefficients of GGT levels with CD4
+ and CD8
+ 
cells were not significantly different from 0 (P>0.05). 
Factors Associated with Elevated AST, ALT, and GGT 
Levels 
 Table  2 shows the results of the multivariate logistic re-
gression models in terms of odds ratios for each of the three 
liver enzymes analyzed. 
 AST. Men were at higher risk for elevated AST than 
women (Odds ratio (OR): 6.31, 95% confidence interval 
(CI): 1.74-22.85) in the HCV monoinfected patients. The 
risk decreased with an increase in CD8
+ cells. The OR corre-
sponding to an increase of a quarter of a logarithm of CD8
+ 
cells was 0.43 (95% CI: 0.24-0.76). In contrast, elevated 
AST in coinfected patients was associated with age and total 
cholesterol. The odds of elevated AST increased by 42% 
with an age increase of five years (OR: 1.42, 95% CI: 1.06-
1.89), whereas a decrease of total cholesterol by 20 mg im-
plied a reduction in risk of 24% (OR: 0.76, 95% CI: 0.61-
0.93). 
Table 2.  Adjusted Odds Ratios (OR) for AST, ALT and GGT 
Elevations in Multivariate Logistic Regression Mod-
els 
 
HCV
+/HIV
- HCV
+/HIV
+ 
 
  OR (95% CI)    OR (95% CI) 
Male  
gender  6.31 (1.74-22.85)  Total  
cholesterol
1  0.76 (0.61-0.93) 
AST  
CD8
+2  0.43 (0.24-0.76)  Age
3  1.42 (1.06-1.89) 
Male  
gender  6.06 (2.14-17.12)  Total  
cholesterol
1  0.79 (0.65-0.97) 
Age
3 0.61  (0.43-0.85)  CD4
+2  1.23 (1.02-1.48) 
ALT  
BMI 1.16  (1.02-1.31)    
 GGT   Alcohol  
consumption  3.78 (1.56-9.19)  Alcohol  
consumption  2.01 (1.02-3.97) 
NOTE. All models were adjusted for gender, alcohol consumption, duration of injec-
tion drug use, BMI, total cholesterol, CD4
+ and CD8
+ cell counts. Only significant 
factors associated with liver enzyme elevations are shown (P<0.05). 
1 OR for an increase of 20 mg/100ml in total cholesterol. 
2 OR for an increase of 0.25*Log10 in CD4+ and CD8+ cells. 
3 OR for five years of age increase. 
 
 ALT. Among HCV monoinfected patients, elevation of 
ALT was associated with age, BMI, and male gender. The 
 
Fig. (1). 95%-Confidence intervals for proportions of elevated AST and ALT levels according to gender and serologic status of HCV and 
HIV infections. Confidence intervals are computed using the normal distribution. 
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estimated OR of men compared to women was 6.06 (95% 
CI: 2.14-17.12). The risk of elevated ALT declined with (in-
creasing) age (OR for an increase of 5 years: 0.61, 95% CI: 
0.43-0.85) and with increasing BMI (OR: 1.16, 95% CI: 
1.02-1.31). With respect to co-infected patients, the two sig-
nificant associated factors were total cholesterol and the 
number of CD4
+ cells. The effect of total cholesterol was 
similar to the one found for AST (OR 0.79; 95% CI: 0.65-
0.97). On the other hand, an increase of a quarter of the loga-
rithm of CD4
+ cells increased the odds for elevated ALT by 
23% (95% CI: 1.02-1.48). 
 GGT. Alcohol consumption increased the odds of ele-
vated GGT values both in the monoinfected and the co-
infected individuals. The corresponding OR were 3.78 (95% 
CI: 1.56-9.19) in monoinfected subjects and 2.01 (95% CI: 
1.02-3.97) in coinfected subjects. 
 The  P-value of the Hosmer-Lemeshow test to check 
model adequacy exceeded 0.05 for all models with more 
than one predictor variable, indicating satisfactory model 
fits. 
DISCUSSION 
  Few data are available regarding the significance of liver 
enzyme alterations among HCV-infected and among 
HIV/HCV co-infected IDUs not referred to liver clinics. In 
this study we evaluated routinary markers of liver disease or 
 
Fig. (2). Correlations of cellular immunity (CD4+ and CD8+ cells) with AST and ALT in HCV+/HIV- monoinfected and HCV+/HIV+ coin-
fected patients. Results are expressed as log(U/l) in case of AST and ALT, and as log(cel/μl) in case of CD4
+ and CD8
+. P-values correspond 
to the hypotheses of zero correlation. 
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liver inflammation to analyze the correlates of AST, ALT 
and GGT elevations. All three parameters have been in-
volved in the development of noninvasive markers of hepatic 
fibrosis [8, 9] but the diagnostic performance of non-
invasive biological scores in active IDUs remains to be de-
termined. 
  In this study with young IDU patients with asymptomatic 
chronic hepatitis C we found that the effect of gender on 
AST and ALT elevations is lost in presence of HIV infec-
tion. 
  Elevations of AST and ALT are more frequent in men 
compared to women from general population [23]. In addi-
tion, gender has been associated with the prognosis of liver 
disease in patients with chronic hepatitis C [24, 25]. 
  Our data also suggest that young IDUs with chronic 
hepatitis C and liver enzymes alterations could be evaluated 
for the presence of liver disease with more variables than 
those that are included in the majority of non-invasive bio-
logical scores for liver fibrosis. For instance, in the HCV 
monoinfected individuals, ALT elevations were associated 
with male gender, higher BMI, and younger age and in dual 
infected patients with higher CD4 cell count and lower total 
cholesterol. 
  Another strength from this study is the fact that patients 
were demographically distinct from series that include older 
and sicker patients with long-term chronic hepatitis C; in this 
population of HIV+ IDUs without AIDS or end-stage liver 
disease, we found that age, total cholesterol, CD4
+, and alco-
hol consumption are predictors of liver enzyme alterations. 
However, GGT elevations are uniquely related to alcohol 
consumption in both the HCV monoinfected and the HCV-
HIV co-infected individuals. 
  In this study ALT elevation decreases with age in the 
monoinfected whereas the AST elevations increase with age 
in the co-infected group. Age, AST and ALT are regularly 
included in the FIB-4, one of the validated clinical indexes 
of liver fibrosis that has proved to correlate with liver fibro-
sis in mono and co-infected patients [26-28]. 
  In the HCV monoinfected patients, BMI was one of the 
predictors for ALT elevations which has been previously 
found in other studies [29]. Although BMI is associated with 
hepatic steatosis [30] and progression of chronic hepatitis C 
it is not considered in the clinical indexes that estimate the 
extent of liver fibrosis. 
  We found that total cholesterol was related to AST and 
ALT elevations in co-infected patients, but not in the mon-
oinfected. On average, higher levels of total cholesterol im-
plied a lower prevalence of liver enzyme elevations suggest-
ing that the HIV-related and/or chronic hepatitis C-related 
dyslipemia may play a role as reported previously in HCV 
monoinfected
  [17, 18] and HCV/HIV co-infected patients 
[19, 20]. 
  With respect to cellular immunity, the absolute number 
of CD8
+ cells was inversely associated with AST elevations 
in monoinfected patients, whereas increases of CD4
+ cells 
and ALT were correlated significantly (P<0.05) in the coin-
fected group. Specific cellular immune responses in the 
course of chronic hepatitis C are crucial for inhibiting virus 
replication, even though it is not clear yet which subtype of 
lymphocytes contribute to control the progression of liver 
disease. Recent studies show the potential role of CD4
+ 
CD25
+ cells (also called CD25
+ Tregs), a small fraction of 
the peripheral CD4
+ cells, as regulatory T cells which can 
diminish hepatic damage by controlling the inflammation or 
stimulating the persistence of HCV infection
 [31-33]. In this 
study, cellular immunity was not measured as a specific re-
sponse on HCV infection. However, absolute numbers of 
CD4
+ and CD8
+ cells were assessed in HIV-positive and 
HIV-seronegative IDUs thus making possible to analyze the 
role of cellular immunity in liver enzyme alterations. 
  Limitations in this cross-sectional study include the fact 
that IDU here analyzed may not be representative of the 
overall population; furthermore, IDU are heterogeneous re-
garding the patterns of substance abuse and severity of ad-
diction. On the other hand, the potential selection bias may 
have influenced the results in the sense of that older patients 
with advanced liver disease were not represented in this 
study. 
  In conclusion, alterations of liver enzymes are frequent in 
young patients with chronic hepatitis C and they are influ-
enced by HIV infection. Further studies are warranted to 
identify noninvasive markers for the clinical management of 
hepatitis C in this population particularly when liver biopsies 
are contraindicated 
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